Loading...
•
Dec 31, 2022
Aura Biosciences Q4 2022 Earnings Report
Aura Biosciences reported its financial results for the fourth quarter and full year 2022, along with clinical development and operational highlights.
Key Takeaways
Aura Biosciences reported a net loss of $16.6 million for the fourth quarter of 2022. The company's cash and cash equivalents and marketable securities totaled $188.8 million as of December 31, 2022, which is expected to fund operations into 2025. The FDA granted Fast Track Designation for Belzupacap Sarotalocan for the treatment of Choroidal Metastasis.
FDA granted Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the treatment of Choroidal Metastasis.
Global Phase 3 Trial in Primary Choroidal Melanoma is on track to begin dosing in 1H 2023.
Positive interim Phase 2 safety and efficacy data with suprachoroidal administration in early-stage choroidal melanoma was presented.
Aura is enrolling a Phase 1 clinical trial of bel-sar for the treatment of non-muscle invasive bladder cancer (NMIBC).
Forward Guidance
Aura believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...